Enovis Business Summary

Enovis Corp (ENOV) operates as a pure-play medical technology company generating revenue through the design, manufacture, and distribution of orthopedic solutions across two primary segments: Prevention & Recovery (P&R) and Reconstructive (Recon). The P&R segment, which accounts for approximately 67% of U.S. revenue, provides bracing, rehabilitation, and injury prevention products, while the Recon segment focuses on high-growth joint replacement and surgical solutions for hips, knees, and extremities. Enovis competes directly with industry giants such as Zimmer Biomet, Stryker, and Johnson & Johnson MedTech (DePuy Synthes). Within this landscape, Enovis maintains a dominant market-leading position in the orthopedic bracing and rehabilitation space while acting as an aggressive, acquisition-fueled challenger in the reconstructive market following its transformative 2024 merger with LimaCorporate. The company’s pedigree is rooted in the operational excellence of its founders, Steven and Mitchell Rales, who established the firm as Colfax Corporation in 1995 before its 2022 pivot to a specialized medtech entity. The current leadership team is led by CEO Damien McDonald, an industry veteran who joined in May 2025 after serving as CEO of LivaNova and holding senior roles at Zimmer and Danaher. Supporting the executive suite are CFO Ben Berry and Chief Administrative Officer Oliver Engert, a former McKinsey Senior Partner appointed in January 2026 to oversee strategy and operational efficiency. The Board of Directors is chaired by Sharon Wienbar and includes notable industry figures such as former Teleflex CEO Liam J. Kelly and former DJO Global CEO Brady R. Shirley, reflecting a board deeply experienced in medical device scaling and institutional growth.